Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Cencora moves billions of dollars in branded, generic, and specialty drugs—and how much it sets aside for opioid litigation—means combing through dense regulatory documents. Cencora SEC filings explained simply is what most investors search for when a new disclosure lands. Stock Titan solves that problem by turning every freshly posted exhibit, footnote, and schedule into plain-English insights within minutes.
Our platform reads each Cencora annual report 10-K simplified, compares segment margins, and highlights cash-flow drivers hidden in accounting tables. You’ll also receive instant alerts the moment a director files Cencora Form 4 insider transactions real-time. Key features include:
- AI-powered summaries that clarify complex wording and accounting changes
- Real-time push notifications for new 10-K, 10-Q, 8-K, and Cencora insider trading Form 4 transactions
- Side-by-side visuals that streamline Cencora earnings report filing analysis
Whether you’re waiting for the next Cencora quarterly earnings report 10-Q filing, researching Cencora executive stock transactions Form 4, or need Cencora 8-K material events explained after an unexpected acquisition, everything is organized in one place. We even map the pages inside the Cencora proxy statement executive compensation section, so pay packages are only a click away. Stop downloading PDFs; start understanding Cencora SEC documents with AI that surfaces the metrics that matter.
Elizabeth S. Campbell, Executive Vice President and director of Cencora, Inc. (COR), reported a sale of 1,886 shares of Cencora common stock on 10/01/2025 at a price of $313.28 per share. Following the transaction, the reporting person beneficially owned 12,824.141 shares. The Form 4 states the sale was executed under a Rule 10b5-1 trading plan adopted on 12/20/2024. The form is signed by Ms. Campbell on 10/03/2025.
Pawan Verma, listed as EVP, Chief Data & Info Officer of Cencora, Inc. (COR), filed an initial Form 3 reporting direct beneficial ownership of 14.05 shares of the issuer's common stock. The event date listed is 10/01/2025. The filing was signed by an attorney-in-fact on 10/03/2025 and includes Exhibit 24 (Power of Attorney).
Cencora, Inc. (COR) filed a Form 144 reporting a proposed sale of 1,886 shares of common stock through Fidelity Brokerage Services LLC on or about 10/01/2025 for an aggregate market value of $590,846.08. The filing shows 193,877,881 shares outstanding, so the shares to be sold represent a de minimis portion of the company.
The securities were acquired on 09/30/2024 through restricted stock vesting from the issuer and the payment is recorded as compensation. The filer certifies they do not possess undisclosed material adverse information. No securities were reported sold by the filer in the prior three months.
Robert P. Mauch, President & CEO and Director of Cencora, Inc. (COR), reported option exercise, open-market sale and related holdings on Form 4. On 09/18/2025 he exercised 3,763 non-qualified stock options at an $86.09 exercise price, receiving 3,763 shares. The same day he sold 5,097 shares at $290 per share under a Rule 10b5-1 trading plan adopted on 11/15/2024. After these transactions he beneficially owned 44,371 shares (before the sale) and 39,274 shares (after the sale), with 3,763 shares exercisable from previously granted options. The Form was signed by an attorney-in-fact on 09/22/2025.
Steven H. Collis, Executive Chairman and Director of Cencora, Inc. (COR), reported transactions on 09/16/2025. The filing shows a sale of 31,350 common shares executed under a Rule 10b5-1 plan adopted 11/25/2024 at a weighted average price of $289.861 (tranche prices ranged from $287.372 to $292.625). The form also records an acquisition (code M) of 29,350 shares tied to a non-qualified stock option with an exercise price of $86.09, exercisable in four equal annual installments beginning 11/13/2020 and expiring 11/13/2026. Following the reported transactions, the reporting person beneficially owned 305,912.665 shares. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Collis on 09/18/2025.
Form 144 notice for proposed sale of securities. The filing reports an intended sale of 5,097 common shares through Fidelity Brokerage Services on 09/18/2025 with an aggregate market value of $1,478,130.00. The document shows total shares outstanding of 193,877,881. Acquisition details list 1,334 shares from restricted stock vesting on 09/30/2023 recorded as compensation, and 3,763 shares from options (granted 11/13/2019) transacted 09/18/2025 for cash. The filing also discloses three prior sales by Robert P. Mauch on 06/18/2025, 07/18/2025 and 08/18/2025 of ~4,968–4,969 shares each with gross proceeds shown. Several identifying fields for the filer and issuer are not provided in the text.
Form 144 notice for Cencora, Inc. (COR) records a proposed sale of 31,350 common shares through Fidelity Brokerage Services on the NYSE with an aggregate market value of $9,140,092.50 and an approximate sale date of 09/16/2025. The filing breaks the lot into 2,000 shares acquired on 09/30/2023 by restricted stock vesting (compensation) and 29,350 shares tied to options granted on 11/13/2019 with a payment date of 09/16/2025 identified as cash.
The form also lists three recent insider sales by Steven Collis: 14,579 shares on 06/24/2025 for $4,266,106.98, 14,578 shares on 07/22/2025 for $4,266,543.26, and 14,579 shares on 08/19/2025 for $4,227,618.42. The notice includes the mandatory representation that the seller is not aware of undisclosed material adverse information.
Cencora, Inc. filed a Form 8-K reporting entry into material agreements. The company executed Amendment No. 2 to the Term Credit Agreement dated September 5, 2025, among the company, the lenders party thereto, and Bank of America, N.A. as administrative agent. On the same date it executed Amendment No. 2 to an Uncommitted Money Market Line Credit Agreement dated September 5, 2025, between the company and Société Générale, New York Branch as lender. The filing references the company's common stock (NYSE: COR), two series of senior notes (2.875% due 2028 and 3.625% due 2032), and certain solicitation and pre-commencement communication rules. The cover page interactive data file is embedded within the Inline XBRL document.
FAQ
What is the current stock price of Cencora (COR)?
What is the market cap of Cencora (COR)?
